MedImmune (AstraZeneca) to acquire Amplimmune for $225M upfront + up to $275M dev milestones (total $500M); strengthened immune-mediated cancer therapy portfolio with anti-PD-1 mAb AMP-514 and B7-family programs.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Dilutive
Pipeline outcome
Assets Stalled
Assessment window: 5yr post-close.
Key facts
AnnouncedAug 26, 2013
ClosedOct 04, 2013
Deal value$500M
Deal typeAcquisition/Merger
Therapeutic areaSolid tumors (immuno-oncology)
IndicationsSolid tumors (immuno-oncology)
Key assetsAMP-514 (anti-PD-1 mAb); B7 family pipeline